The study that was conducted by the researchers from the Barts Cancer Institute, Centre for Molecular Oncology in Queen Mary University, London found out that a simple urine test can detect pancreatic cancer at an early stage.
According to the lead researcher, Dr. Tatjana Crnogorac-Jurcevic, the survival of the people with pancreatic cancer will increase if this cancer is detected early.
Symptoms of this deadly disease are only noticeable at an advanced stage, which cancer has spread widely. The researchers sought a control means for detecting pancreatic cancer and they are hoping that early detection can be an effective treatment.
Pancreatic cancer is the 4th leading cause of death in the United States, after lung, colon and breast cancer. This year, about 44,030 people are diagnosed with pancreatic cancer, and the disease will kill more than 37,660 people, according to the American Cancer Society.
About 95 percent of sufferers die from pancreatic cancer, experts say. It is so deadly because most cases are only treatable in the early stages, there are usually no symptoms. It tends to be discovered at an advanced stage when they can give abdominal pain or jaundice. Currently, there are no general screening tools available.
Pancreatic cancer rates have fallen slightly for men and women in the last 15-25 years. As you age, the risk of developing pancreatic cancer continues. Most patients are older than 45. And nearly 90% of the patient is over 55 years, and the average age of diagnosis is 72.
Men have slightly higher risk of developing pancreatic cancer than women, because woman nowadays, has increased their smoking activity just like men. In the past, when men smoked more than women, the risk gap was wider. There is also a known relationship with race: African Americans are more likely to develop pancreatic cancer than whites. Doctors do not know why but suspected that the highest rates of men are those who smoke and with diabetes. And in women, women who are overweight.
Researchers have learned, to better understand how tumors and pancreatic outreach work. There are a number of ways develop in clinical trials. One of this ways is to focus on leak paths, it will allow pancreatic cancer to normal procedures, which is supported by an antibody- specific for a protein called PD-1 on the surface of pancreatic cancer, such as. Chemotherapy would be more effective since it increases the immune response against the tumor. This work is conducted by the National Cancer Institute.
Researchers in specific therapies for neuroendocrine tumors found out that metastatic nanoparticles work. The idea is that small particles of the matter who's in tumor cells will deliver drugs without harming healthy tissue, killing the toxicity in the body and generally coated it. This investigation is still in animal models.
Another line of search based on biomarkers detect pancreatic cancer, so a blood test or simple urine test could be developed aligned. Unlike other detection of diseases such as colon, breast and prostate cancer, there is no way that this routine determines if a patient has a tumor in the pancreas.The future of medicine is to help people with pancreatic cancer, including genetically develop cancers.